| Old Articles: <Older 3551-3560 Newer> |
|---|
 |
IndustryWeek
April 1, 2007
Traci Purdum |
Beaker Counters Bristol-Myers Squibb incorporates procurement initiative.   |
Chemistry World
March 13, 2007 |
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. |
The Motley Fool
March 13, 2007
Brian Lawler |
Panacos Springs Ahead Panacos advances its lead drug program. |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
Bio-IT World
March 2007
Kevin Davies |
Biogen-Idec's Innovation Incubator In this imaginative new business model, Biogen-Idec will provide facilities, funding, and expertise to help scientific entrepreneurs develop new therapeutic candidates. |
Bio-IT World
March 2007
Robert M. Frederickson |
The Market for Automation The QIAcube is a benchtop robotic system for fully automated sample preparation using the Qiagen spin-column kits that are currently in wide use. |
Bio-IT World
March 2007
Michael A. Greeley |
Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities. |
Bio-IT World
March 2007 |
Briefs Metabolomics Resources... LIMS Collaboration... Biomarker Collaboration... Analysis Update... |
Reason
March 2007
Radley Balko |
Cold Comfort Given all the abuse the drug companies were taking because of meth cooks' illegal use of their products, you could almost forgive Pfizer for putting a useless product on the shelves. |
Chemistry World
March 12, 2007 |
Akzo Nobel Sells Medicines Business to Schering Plough US drug giant Schering-Plough is to buy Dutch chemical company Akzo Nobel's pharmaceuticals and animal health business, Organon BioSciences, for 11 billion euros. |
| <Older 3551-3560 Newer> Return to current articles. |
